2,140
Views
4
CrossRef citations to date
0
Altmetric
Tuberculosis

Global DNA hypomethylation of Alu and LINE-1 transposable elements as an epigenetic biomarker of anti-tuberculosis drug-induced liver injury

ORCID Icon, , , , , , & show all
Pages 1862-1872 | Received 11 May 2021, Accepted 30 Aug 2021, Published online: 17 Sep 2021

References

  • Doherty AM, Kelly J, McDonald C, et al. A review of the interplay between tuberculosis and mental health. Gen Hosp Psychiat. 2013;35:398–406.
  • McIlleron H, Meintjes G, Burman WJ, et al. Complications of antiretroviral therapy in patients with tuberculosis: drug interactions, toxicity, and immune reconstitution inflammatory syndrome. J Infect Dis. 2007;196:S63–S75.
  • Yee D, Valiquette C, Pelletier M, et al. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med. 2003;167:1472–1477.
  • Gulbay BE, Gurkan OU, Yildiz OA, et al. Side effects due to primary antituberculosis drugs during the initial phase of therapy in 1149 hospitalized patients for tuberculosis. Respir Med. 2006;100:1834–1842.
  • Senior JR. Alanine aminotransferase: a clinical and regulatory tool for detecting liver injury–past, present, and future. Clin Pharmacol Ther. 2012;92:332–339.
  • Hanley AJ, Williams K, Festa A, et al. Elevations in markers of liver injury and risk of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes. 2004;53:2623–2632.
  • Sattar N, Scherbakova O, Ford I, et al. Elevated alanine aminotransferase predicts new-onset type 2 diabetes independently of classical risk factors, metabolic syndrome, and C-reactive protein in the west of Scotland coronary prevention study. Diabetes. 2004;53:2855–2860.
  • Wang L, McLeod HL, Weinshilboum RM. Genomics and drug response. N Engl J Med. 2011;364:1144–1153.
  • Evans WE, McLeod HL. Pharmacogenomics–drug disposition, drug targets, and side effects. N Engl J Med. 2003;348:538–549.
  • Daly AK. Drug-induced liver injury: past, present and future. Pharmacogenomics. 2010;11:607–611.
  • Nanashima K, Mawatari T, Tahara N, et al. Genetic variants in antioxidant pathway: risk factors for hepatotoxicity in tuberculosis patients. Tuberculosis. 2012;92:253–259.
  • Huai C, Wei Y, Li M, et al. Genome-wide analysis of DNA methylation and antituberculosis drug-induced liver injury in the Han Chinese population. Clin Pharmacol Ther. 2019;106:1389–1397.
  • Li Y, Li Y, Zheng G, et al. Cytochrome p450 1A1 and 1B1 promoter CpG island methylation regulates rat liver injury induced by isoniazid. Mol Med Rep. 2018;17:753–762.
  • Zhang J, Zhu X, Li Y, et al. Correlation of CpG island methylation of the Cytochrome P450 2E1/2D6 genes with liver injury induced by anti-tuberculosis drugs: a nested case-control study. Int J Environ Res Public Health. 2016;13:776.
  • He L, Gao L, Shi Z, et al. Involvement of cytochrome P450 1A1 and glutathione S-transferase P1 polymorphisms and promoter hypermethylation in the progression of anti-tuberculosis drug-induced liver injury: a case-control study. PLoS One. 2015;10:e0119481.
  • Portela A, Esteller M. Epigenetic modifications and human disease. Nat Biotechnol. 2010;28:1057–1068.
  • Weisenberger DJ, Campan M, Long TI, et al. Analysis of repetitive element DNA methylation by MethyLight. Nucleic Acids Res. 2005;33:6823–6836.
  • Gaudet F, Hodgson JG, Eden A, et al. Induction of tumors in mice by genomic hypomethylation. Science. 2003;300:489–492.
  • Zheng Y, Hlady RA, Joyce BT, et al. DNA methylation of individual repetitive elements in hepatitis C virus infection-induced hepatocellular carcinoma. Clin Epigenetics. 2019;11:145.
  • Udomsinprasert W, Kitkumthorn N, Mutirangura A, et al. Global methylation, oxidative stress, and relative telomere length in biliary atresia patients. Sci Rep. 2016;6:26969.
  • Anwar SL, Hasemeier B, Schipper E, et al. LINE-1 hypomethylation in human hepatocellular carcinomas correlates with shorter overall survival and CIMP phenotype. PLoS One. 2019;14:e0216374.
  • World Health Organization (WHO). Guidelines for treatment of drugsusceptible tuberculosis and patient care. Geneva: WHO Press; 2017. https://doi.org/https://doi.org/10.1586/17476348.1.1.85.
  • World Health Organization (WHO). Latent tuberculosis infection: updated and consolidated guidelines for programmatic management. Geneva: WHO Press; 2018. https://doi.org/https://doi.org/10.1056/NEJMcp021045.
  • Services, Do.M. Clinical practice guideline of tuberculosis treatment in Thailand 104, (2018).
  • Pachkoria K, Lucena MI, Crespo E, et al. Analysis of IL-10, IL-4 and TNF-alpha polymorphisms in drug-induced liver injury (DILI) and its outcome. J Hepatol. 2008;49:107–114.
  • Zhang D, Hao J, Hou R, et al. The role of NAT2 polymorphism and methylation in anti-tuberculosis drug-induced liver injury in Mongolian tuberculosis patients. J Clin Pharm Ther. 2020;45:561–569.
  • Sharma V, Kaur R, Sharma VL. Ameliorative potential of Adhatoda vasica against anti-tubercular drugs induced hepatic impairments in female Wistar rats in relation to oxidative stress and xeno-metabolism. J Ethnopharmacol. 2021;270:113771.
  • Furlan D, Trapani D, Berrino E, et al. Oxidative DNA damage induces hypomethylation in a compromised base excision repair colorectal tumourigenesis. Br J Cancer. 2017;116:793–801.
  • Zhang Z, Saier MH Jr. A novel mechanism of transposon-mediated gene activation. PLoS Genet. 2009;5:e1000689.
  • Bourque G, Burns KH, Gehring M, et al. Ten things you should know about transposable elements. Genome Biol. 2018;19:199.
  • Lokk K, Modhukur V, Rajashekar B, et al. DNA methylome profiling of human tissues identifies global and tissue-specific methylation patterns. Genome Biol. 2014;15:r54.